| Identification | Back Directory | [Name]
ARRY-424704, ARRY-704 | [CAS]
869357-68-6 | [Synonyms]
CS-396
AZD8330
ARRY704
ARRY-704
ARRY424704
ARRY-424704
AZD8330(ARRY-424704
ARRY-424704, ARRY-704
ARRY-424704, ARRY-704
AZD8330
ARRY-424704, ARRY-704 ISO 9001：2015 REACH
AZD8330/ARRY-424704/arry-704/AZD8330/AZD-8330
AZD8330;ARRY-424704; ARRY424704;ARRY704; AZD8330
ARRY-424704; ARRY-704; AZD-8330; ARRY424704; ARRY704; AZD 8330
2-((2-Fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-
2-(2-Fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
3-Pyridinecarboxamide, 2-[(2-fluoro-4-iodophenyl)amino]-1,6-dihydro-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo- | [EINECS(EC#)]
642-441-7 | [Molecular Formula]
C16H17FIN3O4 | [MDL Number]
MFCD18384989 | [MOL File]
869357-68-6.mol | [Molecular Weight]
461.23 |
| Chemical Properties | Back Directory | [density ]
1.732 | [storage temp. ]
Store at -20°C | [solubility ]
≥23.05 mg/mL in DMSO; insoluble in H2O; ≥46.1 mg/mL in EtOH | [form ]
solid | [pka]
14.31±0.10(Predicted) | [color ]
Off-white to pink |
| Hazard Information | Back Directory | [Description]
AZD 8330 is a selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM). It blocks phosphorylation of ERK1/2 and inhibits proliferation of certain cancer cells.1 AZD 8330 is orally bioavailable, inhibits ERK phosphorylation in vivo, and reduces tumor growth in a Calu-6 nude rat xenograft model.2 | [Uses]
AZD8330 is an orally active and selective MEK inhibitor. | [Definition]
ChEBI: 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide is a pyridinecarboxamide. It is functionally related to a nicotinamide. | [target]
ERK phosphorylation | [References]
1. feng k, wang c, zhou h, yang j, dong l, zhou k, et al. [effect of erk1/2 inhibitor azd8330 on human burkitt's lymphoma cell line raji cells and its mechanism]. zhonghua xue ye xue za zhi 2015,36:148-152.2. cohen rb, aamdal s, nyakas m, cavallin m, green d, learoyd m, et al. a phase i dose-finding, safety and tolerability study of azd8330 in patients with advanced malignancies. eur j cancer 2013,49:1521-1529. |
|
|